18.07.02 · organismal-bio / endocrine

Hypothalamic-pituitary axis: releasing hormones, tropic hormones, and feedback regulation

stub3 tiersLean: nonepending prereqs

Anchor (Master): Guyton, A. C. & Hall, J. E. — Textbook of Medical Physiology, 14th ed. (2021), Ch. 74-76

Intuition Beginner

The hypothalamus is the brain's link to the hormone system. It sends releasing hormones to the pituitary gland, which responds by releasing tropic hormones that stimulate other glands — the thyroid, adrenal cortex, and gonads. Those target glands produce the final hormones acting on the body.

The system regulates itself through negative feedback: when target-gland hormone levels rise, they signal the hypothalamus and pituitary to slow down, keeping concentrations in a narrow range like a thermostat.

The pituitary has two lobes. The anterior pituitary synthesises its own hormones under hypothalamic instruction. The posterior pituitary stores and releases two hormones (ADH and oxytocin) made in the hypothalamus and transported down nerve fibres.

Visual Beginner

The hypothalamic-hypophyseal portal system is a specialised capillary network carrying blood directly from the hypothalamus to the anterior pituitary without first entering the systemic circulation. This delivers tiny quantities of releasing hormone at high local concentration, enabling precise neuroendocrine control with nanomolar amounts.

Worked example Beginner

Trace the hypothalamic-pituitary-thyroid (HPT) axis from stimulus to feedback:

The hypothalamus detects low circulating thyroid hormone levels.
Hypothalamus secretes thyrotropin-releasing hormone (TRH) into the portal vessels.
Anterior pituitary responds to TRH by releasing thyroid-stimulating hormone (TSH) into the bloodstream.
Thyroid gland responds to TSH by producing thyroxine (T4) and triiodothyronine (T3).
T3 and T4 act on cells throughout the body, increasing metabolic rate, heart rate, and heat production.
Negative feedback: Rising T3 and T4 inhibit both TRH release from the hypothalamus and TSH release from the pituitary.

Each step amplifies the signal. A small amount of TRH triggers a larger TSH release, which drives even larger T4/T3 output. The feedback loop at the end ensures the response is self-limiting.

Check your understanding Beginner

Exercise (easy, multiple choice).

Negative feedback in the hypothalamic-pituitary axis means that:

A. Target-gland hormones stimulate further releasing hormone secretion B. Target-gland hormones inhibit further secretion at the pituitary and hypothalamus C. The pituitary produces hormones without any regulation D. Releasing hormones directly suppress target-gland activity

Hint

"Negative" feedback means the output opposes its own production. Where do target-gland hormones act?

Answer

B. Target-gland hormones inhibit further secretion at the pituitary and hypothalamus. When the thyroid produces enough T3/T4, or the adrenal cortex produces enough cortisol, these hormones travel back and suppress further stimulation at both upstream levels. This is negative feedback — the output of the system acts to reduce its own production.

Formal definition Intermediate+

The five hypothalamic-pituitary axes

The hypothalamic-pituitary system comprises five functionally distinct axes, each defined by a specific releasing (or inhibiting) hormone, a corresponding anterior pituitary tropic hormone, and the target-gland end product:

Axis	Releasing hormone	Pituitary hormone	Target gland	Target-gland hormone
HPT (thyroid)	TRH	TSH	Thyroid	T3, T4
HPA (adrenal)	CRH	ACTH	Adrenal cortex	Cortisol
HPG (gonadal)	GnRH	FSH, LH	Gonads	Oestradiol, testosterone, progesterone
GH (growth)	GHRH / somatostatin	GH	Liver, tissues	IGF-1
Prolactin	Dopamine (PIH) / TRH	Prolactin	Breast	Milk

Each axis is regulated by negative feedback operating at one or both of two levels:

Long-loop feedback: the target-gland hormone (e.g., cortisol, T3) inhibits both the pituitary and hypothalamus. This is the dominant feedback mode.
Short-loop feedback: the pituitary hormone itself (e.g., ACTH) inhibits the hypothalamus, providing an additional regulatory tier before the target gland responds.

Hypothalamic releasing and inhibiting hormones

The hypothalamus produces six major releasing and inhibiting hormones that control anterior pituitary secretion:

GnRH (gonadotropin-releasing hormone): stimulates FSH and LH release. Pulsatile secretion is essential — continuous GnRH suppresses gonadotropin release through receptor downregulation.
TRH (thyrotropin-releasing hormone): stimulates TSH release and, at higher concentrations, prolactin release.
CRH (corticotropin-releasing hormone): stimulates ACTH release. CRH secretion follows a circadian rhythm, peaking in the early morning and reaching a nadir at midnight. The rhythm is driven by pulsatile CRH release entrained by the suprachiasmatic nucleus.
GHRH (growth hormone-releasing hormone): stimulates GH release from somatotrophs.
Somatostatin (SST, growth hormone-inhibiting hormone): inhibits GH release and also inhibits TSH, insulin, and glucagon secretion. The balance between GHRH and somatostatin determines the net GH output.
Dopamine (prolactin-inhibiting hormone, PIH): tonically inhibits prolactin release. This is the only axis where the dominant hypothalamic signal is inhibitory rather than stimulatory. Interruption of the hypothalamic-pituitary stalk (e.g., by compression from a tumour) causes prolactin elevation because the tonic dopaminergic brake is removed, while all other anterior pituitary hormones decline due to loss of stimulatory input.

Anterior pituitary hormones

The anterior pituitary (adenohypophysis) contains five distinct hormone-producing cell types:

Corticotrophs: produce ACTH. ACTH is cleaved from the precursor pro-opiomelanocortin (POMC), which also yields beta-lipotropin and beta-endorphin.
Thyrotrophs: produce TSH.
Gonadotrophs: produce FSH and LH.
Somatotrophs: produce growth hormone (GH).
Lactotrophs: produce prolactin.

ACTH, TSH, FSH, and LH are glycoprotein hormones sharing a common alpha subunit but possessing unique beta subunits that confer receptor specificity. GH and prolactin are single-chain polypeptides with structural homology to each other.

Posterior pituitary hormones

The posterior pituitary (neurohypophysis) releases two peptide hormones produced by hypothalamic magnocellular neurons:

ADH (antidiuretic hormone / vasopressin): synthesised primarily by neurons of the supraoptic nucleus. ADH promotes water reabsorption in the renal collecting ducts via V2 receptors (activating adenylate cyclase and inserting aquaporin-2 channels into the apical membrane) and causes vasoconstriction at high concentrations via V1 receptors. Secretion is regulated by plasma osmolarity (detected by osmoreceptors in the organum vasculosum of the lamina terminalis and the subfornical organ) and by blood volume and pressure (detected by atrial and carotid baroreceptors).
Oxytocin: synthesised primarily by neurons of the paraventricular nucleus. Oxytocin stimulates uterine smooth muscle contraction during labour and myoepithelial cell contraction in the breast during lactation (milk ejection reflex). Both functions involve positive feedback: cervical stretch during labour triggers further oxytocin release via the Ferguson reflex, and infant suckling triggers further release via a neuroendocrine reflex until milk ejection is complete.

Pulsatile secretion and frequency decoding

All hypothalamic releasing hormones are secreted in pulses rather than continuously. The pulse frequency carries biological information decoded by pituitary target cells. The best-characterised example is GnRH:

Rapid pulses (one every 30-60 minutes) preferentially stimulate LH secretion.
Slow pulses (one every 2-3 hours) preferentially stimulate FSH secretion.
Continuous GnRH exposure suppresses both LH and FSH through receptor downregulation.

This frequency-dependent response is exploited therapeutically. Continuous GnRH agonists (e.g., leuprolide) produce an initial stimulation (the "flare") followed by sustained suppression — the basis of androgen-deprivation therapy for prostate cancer and ovarian suppression in endometriosis and precocious puberty. Conversely, pulsatile GnRH administration (via pump) restores fertility in patients with hypogonadotropic hypogonadism.

Key theorem with proof Intermediate+

Theorem (Hierarchical feedback set-point). In a three-tier hormone cascade (releasing hormone $H_{1}$ , tropic hormone $H_{2}$ , target-gland hormone $H_{3}$ ) with negative feedback from $H_{3}$ to both the hypothalamic and pituitary tiers, the steady-state target-gland hormone concentration is

[H_{3}]_{ss} = \frac{k _{1} k _{2} r _{0}}{d _{1} d _{2} d _{3} + k _{2} ( d _{1} γ _{2} + k _{1} γ _{1} )},

where $r_{0}$ is the baseline releasing-hormone secretion rate, $k_{1}, k_{2}$ are stimulation gains at each tier, $d_{1}, d_{2}, d_{3}$ are clearance rate constants, $γ_{1}$ is hypothalamic feedback sensitivity, and $γ_{2}$ is pituitary feedback sensitivity. The equilibrium is stable whenever $γ_{1}, γ_{2} > 0$ .

Proof. The dynamics are:

\frac{d [ H _{1} ]}{d t} = r_{0} - γ_{1} [H_{3}] - d_{1} [H_{1}]

\frac{d [ H _{2} ]}{d t} = k_{1} [H_{1}] - γ_{2} [H_{3}] - d_{2} [H_{2}]

\frac{d [ H _{3} ]}{d t} = k_{2} [H_{2}] - d_{3} [H_{3}]

At steady state all derivatives vanish. From the third equation: $[H_{2}]_{ss} = d_{3} [H_{3}]_{ss} / k_{2}$ . From the second: $k_{1} [H_{1}]_{ss} = d_{2} [H_{2}]_{ss} + γ_{2} [H_{3}]_{ss}$ , giving $[H_{1}]_{ss} = [H_{3}]_{ss} (d_{2} d_{3} / k_{2} + γ_{2}) / k_{1}$ . From the first: $d_{1} [H_{1}]_{ss} = r_{0} - γ_{1} [H_{3}]_{ss}$ , giving

\frac{d _{1} [ H _{3} ] _{ss} ( d _{2} d _{3} / k _{2} + γ _{2} )}{k _{1}} + γ_{1} [H_{3}]_{ss} = r_{0} .

Multiplying through by $k_{1} k_{2}$ and collecting $[H_{3}]_{ss}$ :

[H_{3}]_{ss} (d_{1} d_{2} d_{3} + d_{1} k_{2} γ_{2} + k_{1} k_{2} γ_{1}) = k_{1} k_{2} r_{0},

which yields the stated result. If $[H_{3}]$ transiently exceeds $[H_{3}]_{ss}$ , both feedback terms ( $γ_{1} [H_{3}]$ , $γ_{2} [H_{3}]$ ) increase, suppressing $H_{1}$ and $H_{2}$ production and thereby reducing $H_{3}$ back toward $[H_{3}]_{ss}$ . The converse holds if $[H_{3}]$ falls below set point. The linearised Jacobian has negative diagonal entries and its characteristic polynomial satisfies the Routh-Hurwitz conditions for physiological parameter ranges, confirming stability. $□$

Clinical interpretation. In primary hypothyroidism the thyroid's responsiveness to TSH is reduced (lower $k_{2}$ ), so $[H_{3}]_{ss}$ falls. The diminished feedback allows $[H_{2}]_{ss}$ (TSH) to rise — the classic laboratory pattern of elevated TSH with low T4. In secondary hypothyroidism (pituitary failure, reduced $k_{1}$ ), both TSH and T4 fall. The theorem predicts this distinction from the structure of the equations alone.

Exercises Intermediate+

Exercise 1 (medium, multiple choice).

A patient has a pituitary adenoma compressing the hypothalamic-pituitary stalk. Which anterior pituitary hormone would you expect to be elevated, and why?

A. TSH, because TRH stimulation increases B. ACTH, because CRH accumulates proximal to the compression C. Prolactin, because tonic dopaminergic inhibition from the hypothalamus is interrupted D. GH, because somatostatin delivery is blocked

Hint

Most hypothalamic signals to the anterior pituitary are stimulatory. One is inhibitory. What happens when an inhibitory signal is blocked?

Answer

C. Prolactin. Dopamine (prolactin-inhibiting hormone) is the only hypothalamic signal that tonically suppresses its target. Stalk compression interrupts dopaminergic delivery, removing the brake on lactotrophs. Prolactin rises while all other anterior pituitary hormones (TSH, ACTH, FSH/LH, GH) decline because they depend on stimulatory hypothalamic input (TRH, CRH, GnRH, GHRH) that is also interrupted. This "stalk effect" is a classic diagnostic pattern: prolactin is modestly elevated (usually < 200 ng/mL), distinguishing it from a true prolactinoma (> 200 ng/mL).

Exercise 2 (medium, short answer).

Explain why continuous administration of a GnRH agonist such as leuprolide suppresses gonadal function rather than stimulating it, despite the drug being an agonist at the GnRH receptor.

Hint

Pituitary gonadotrophs interpret GnRH pulse frequency as a signal. What does continuous exposure do to GnRH receptors?

Answer

GnRH receptors on pituitary gonadotrophs are G-protein-coupled receptors subject to desensitisation and downregulation. Continuous agonist exposure causes receptor phosphorylation by G-protein-coupled receptor kinases, beta-arrestin binding, and receptor internalisation. The gonadotrophs lose responsiveness, and both LH and FSH secretion decline. This produces an initial "flare" (transient LH/FSH rise) followed by sustained suppression. The gonads, deprived of stimulation, produce less testosterone or oestrogen. This pharmacological castration is exploited in prostate cancer, endometriosis, and precocious puberty.

Exercise 3 (medium, short answer).

Distinguish short-loop from long-loop negative feedback using the HPA axis as an example. What is the functional advantage of having both?

Hint

Short-loop feedback acts at one tier above the hormone producing it. Long-loop feedback skips a tier.

Answer

In the HPA axis, long-loop feedback is cortisol inhibiting both the hypothalamus (CRH) and pituitary (ACTH). Short-loop feedback is ACTH itself inhibiting CRH release from the hypothalamus. Short-loop feedback provides an early braking signal: ACTH begins to suppress CRH before cortisol levels have risen enough to provide long-loop feedback. This two-tiered arrangement prevents overshoot. Without short-loop feedback, the system would depend entirely on the delayed cortisol signal, producing wider oscillations around the set point.

Exercise 4 (medium, short answer).

ADH is synthesised in the hypothalamus but released from the posterior pituitary. If the pituitary stalk is severed above the posterior pituitary, what happens to ADH levels and why?

Hint

ADH travels down axons from hypothalamic neurons to posterior pituitary nerve terminals. Where are the synthesising cell bodies?

Answer

Stalk severance disrupts the axonal transport of ADH from hypothalamic neurons to the posterior pituitary, producing acute ADH deficiency and central diabetes insipidus — excessive dilute urine output with rising plasma osmolarity and thirst. However, the hypothalamic neuron cell bodies (supraoptic and paraventricular nuclei) remain intact and continue synthesising ADH. Over weeks to months, the severed axon endings can regenerate into adjacent vascular tissue and re-establish functional release sites, often resolving the diabetes insipidus. This recovery potential contrasts with nephrogenic diabetes insipidus (renal V2 receptor resistance), which is permanent.

Exercise 5 (hard, short answer).

A patient presents with fatigue, weight gain, and cold intolerance. Laboratory tests show TSH = 45 mIU/L (reference 0.4-4.0) and free T4 = 2.1 pmol/L (reference 9.0-25.0). Is the lesion in the thyroid, pituitary, or hypothalamus? Explain using the feedback framework.

Hint

The direction of TSH deviation from normal reveals whether the pituitary is responding to feedback or is itself the source of the problem.

Answer

Primary hypothyroidism (thyroid lesion). The TSH is markedly elevated while free T4 is low. In the feedback framework, the pituitary detects the low T4 and mounts a compensatory increase in TSH secretion — the pituitary is functioning normally, but the thyroid cannot respond. This pattern (low target-gland hormone, high tropic hormone) identifies the lesion as distal to the pituitary. If the lesion were in the pituitary (secondary hypothyroidism), both TSH and T4 would be low. If it were in the hypothalamus (tertiary hypothyroidism), TSH might be low or inappropriately normal despite low T4, because TRH drive is absent.

Exercise 6 (hard, symbolic).

Using the hierarchical feedback model from the Key Theorem, show that if the target gland loses all responsiveness ( $k_{2} \to 0$ ), the pituitary hormone concentration $[H_{2}]_{ss}$ rises without bound in the absence of direct feedback on the pituitary ( $γ_{2} = 0$ ), but remains finite when $γ_{2} > 0$ . What is the clinical implication?

Hint

Set $k_{2} = 0$ in the steady-state equations and solve for $[H_{2}]_{ss}$ with and without the $γ_{2}$ term.

Answer

When $k_{2} = 0$ , the third equation gives $[H_{3}]_{ss} = 0$ (no target-gland hormone is produced). The first equation gives $[H_{1}]_{ss} = r_{0} / d_{1}$ (no feedback inhibition).

With $γ_{2} = 0$ : $d_{2} [H_{2}]_{ss} = k_{1} [H_{1}]_{ss} = k_{1} r_{0} / d_{1}$ . So $[H_{2}]_{ss} = k_{1} r_{0} / (d_{1} d_{2})$ , which is finite but elevated — the pituitary runs at its maximum unrestrained rate. (It does not diverge to infinity, but it is maximally elevated.)

With $γ_{2} > 0$ and $[H_{3}]_{ss} = 0$ : the $γ_{2}$ term has no effect because there is no $H_{3}$ to provide feedback. So $[H_{2}]_{ss}$ is the same: $k_{1} r_{0} / (d_{1} d_{2})$ .

The clinical implication is that in complete primary gland failure, the tropic hormone rises to its maximal unrestrained level because there is no feedback hormone to provide inhibition at any tier. In primary hypothyroidism, TSH can reach 100+ mIU/L — the pituitary thyrotrophs are producing TSH at their maximum capacity because there is no T3/T4 to brake them. This is why TSH is the most sensitive screening test for thyroid dysfunction: it amplifies the signal of even mild target-gland impairment.

Pituitary pathology and dynamic endocrine testing Master

Pituitary adenomas

Pituitary adenomas are benign tumours of anterior pituitary cells classified by size (microadenoma < 10 mm, macroadenoma >= 10 mm) and by hormonal output. They account for 10-15% of all intracranial tumours and are the most common cause of hypothalamic-pituitary dysfunction in adults.

Prolactinoma is the most common functioning pituitary adenoma. Prolactin-secreting lactotroph adenomas cause hyperprolactinaemia, producing galactorrhoea (inappropriate milk production), amenorrhoea (absence of menstruation), and infertility in women; in men, they cause hypogonadism (low testosterone from prolactin-mediated suppression of GnRH). Diagnosis is confirmed by a serum prolactin level above 200 ng/mL. Treatment is primarily medical: dopamine agonists (cabergoline, bromocriptine) exploit the tonic inhibitory control of dopamine on lactotrophs, reducing both prolactin secretion and tumour size in most patients. Surgery is reserved for dopamine-agonist-resistant tumours.

Cushing disease (pituitary ACTH-secreting adenoma) causes bilateral adrenal hyperplasia and cortisol excess. The clinical presentation includes central obesity, moon facies, buffalo hump, proximal myopathy, thin skin with striae, hyperglycaemia, and hypertension. The diagnostic challenge is distinguishing Cushing disease from ectopic ACTH production and adrenal adenomas. The dexamethasone suppression test exploits differential feedback sensitivity: low-dose dexamethasone (1 mg overnight) fails to suppress cortisol in all causes of Cushing syndrome; high-dose dexamethasone (8 mg overnight) suppresses cortisol in most pituitary adenomas (which retain partial feedback sensitivity) but not in ectopic ACTH or adrenal tumours. Confirmatory localisation uses inferior petrosal sinus sampling (IPSS) to demonstrate a central-to-peripheral ACTH gradient.

Acromegaly (GH-secreting adenoma in adults) produces enlargement of the hands, feet, and facial bones (jaw, brow ridges), coarsening of facial features, carpal tunnel syndrome, organomegaly (heart, liver, tongue), and insulin resistance. In children with open epiphyseal plates, the same excess produces gigantism (excessive height). Diagnosis requires demonstrating failure of GH suppression below 1 ng/mL during an oral glucose tolerance test, elevated IGF-1, and pituitary imaging. Treatment is trans-sphenoidal surgery, with adjunctive somatostatin receptor ligands (octreotide, lanreotide) or GH receptor antagonists (pegvisomant) for persistent disease.

SIADH and diabetes insipidus

Disorders of ADH regulation produce two mirror-image syndromes defined by the relationship between ADH secretion and plasma osmolarity.

SIADH (syndrome of inappropriate antidiuretic hormone) is characterised by excessive ADH secretion relative to plasma osmolarity, causing water retention, dilutional hyponatraemia (serum sodium < 135 mmol/L), and concentrated urine (urine osmolarity > serum osmolarity despite low serum sodium). Common causes include small cell lung cancer (ectopic ADH production), CNS disorders (stroke, haemorrhage, infection), and medications (SSRIs, carbamazepine). Treatment is fluid restriction, and in severe cases, vasopressin receptor antagonists (conivaptan, tolvaptan).

Central diabetes insipidus results from insufficient ADH secretion (hypothalamic or pituitary lesions: craniopharyngioma, pituitary surgery, head trauma, Sheehan syndrome). Patients produce large volumes of dilute urine (polyuria, > 3 L/day) with compensatory polydipsia. Serum sodium is normal or elevated. The water deprivation test distinguishes central from nephrogenic diabetes insipidus: after fluid restriction, exogenous desmopressin (ADH analogue) concentrates the urine in central DI (the kidneys can respond to ADH) but not in nephrogenic DI (renal resistance to ADH).

Nephrogenic diabetes insipidus results from renal resistance to ADH (V2 receptor mutations, lithium toxicity, hypercalcaemia). The kidneys cannot respond to ADH regardless of how much is secreted. Treatment targets the underlying cause; thiazide diuretics paradoxically reduce urine output by inducing mild volume depletion, which enhances proximal tubular sodium and water reabsorption and reduces delivery to the collecting duct.

Hypopituitarism and Sheehan syndrome

Hypopituitarism is deficiency of one or more anterior pituitary hormones. Causes include pituitary adenomas (and their surgical treatment), radiation, traumatic brain injury, and infiltrative diseases (sarcoidosis, haemochromatosis). The order of hormone loss typically follows a predictable pattern: GH first, then FSH/LH, then TSH, then ACTH. This vulnerability gradient is thought to reflect differential sensitivity of pituitary cell types to compressive and vascular insult. ACTH deficiency is the most dangerous because cortisol is essential for blood pressure maintenance during stress — untreated secondary adrenal insufficiency can be fatal during intercurrent illness.

Sheehan syndrome is postpartum hypopituitarism caused by ischaemic necrosis of the anterior pituitary. The pituitary enlarges during pregnancy (lactotroph hyperplasia) but has a tenuous blood supply via the low-pressure portal system. Severe postpartum haemorrhage causes hypotension, and the enlarged pituitary infarcts. The classic presentation is failure of postpartum lactation, followed by amenorrhoea, fatigue, and signs of progressive pituitary hormone loss. The posterior pituitary, supplied by the high-pressure systemic circulation via the inferior hypophyseal arteries, is typically spared — ADH deficiency is uncommon in Sheehan syndrome.

Growth hormone deficiency and excess

GH deficiency in children presents as growth failure (height below the 3rd centile for age) with normal body proportions. Diagnosis requires demonstration of inadequate GH response to two provocative stimuli (insulin-induced hypoglycaemia, arginine, clonidine, or glucagon stimulation tests), plus low IGF-1 and IGFBP-3. Treatment is recombinant GH injection. In adults, GH deficiency (from pituitary disease) causes reduced lean body mass, increased fat mass, reduced exercise capacity, and impaired quality of life — GH replacement is approved for severe adult GH deficiency.

GH excess in children causes gigantism (before epiphyseal closure) and in adults causes acromegaly. The distinction is purely anatomical: growth plates open versus fused. The underlying pathology (GH-secreting pituitary adenoma, or rarely hypothalamic GHRH-secreting tumour) is the same.

CRH-ACTH-cortisol circadian rhythm and the stress response

Cortisol secretion follows a circadian rhythm with peak levels in the early morning (6-8 AM) and a nadir at midnight. The rhythm is generated by pulsatile CRH release from the hypothalamus, entrained by the suprachiasmatic nucleus via neural projections. Each cortisol pulse has a half-life of approximately 60-90 minutes, and the ultradian pulsatility (roughly hourly pulses) is superimposed on the circadian envelope.

The stress response overrides the circadian pattern. Physical stress (surgery, trauma, hypoglycaemia, infection) activates brainstem nuclei (nucleus tractus solitarius, locus coeruleus) that stimulate hypothalamic CRH release, producing a rapid increase in ACTH and cortisol. The cortisol response mobilises glucose (gluconeogenesis, glycogenolysis), suppresses non-essential processes (immune response, reproduction, growth), and maintains vascular responsiveness to catecholamines. Chronic stress produces sustained HPA activation, contributing to metabolic syndrome, immunosuppression, and mood disorders.

The circadian rhythm has diagnostic utility: the late-night salivary cortisol test exploits the fact that cortisol should be at its nadir at midnight. An elevated late-night cortisol suggests Cushing syndrome (loss of normal circadian rhythm is one of the earliest abnormalities). The overnight dexamethasone suppression test similarly tests whether the feedback loop can suppress the early-morning cortisol peak.

Dynamic endocrine testing

Dynamic endocrine tests exploit the feedback structure of the hypothalamic-pituitary axes to localise the site of dysfunction. They fall into two categories:

Suppression tests assess whether negative feedback is intact. The dexamethasone suppression test (low-dose and high-dose) for Cushing syndrome is the paradigmatic example. If cortisol does not suppress after dexamethasone, the feedback loop is disrupted — either because an autonomous tumour is producing cortisol (adrenal adenoma), because a pituitary adenoma is producing ACTH with partial feedback resistance (Cushing disease), or because an ectopic source is producing ACTH without feedback sensitivity.

Stimulation tests assess the reserve capacity of an axis. The TRH stimulation test measures the TSH response to exogenous TRH injection. In normal subjects, TRH produces a brisk TSH rise. In hyperthyroidism (excess T3/T4 suppressing the pituitary), the TSH response is blunted or absent. In hypothyroidism, the response is exaggerated (thyrotrophs are already primed by low feedback). The ACTH stimulation test (synacthen test) assesses adrenal reserve: exogenous ACTH should stimulate cortisol production. In primary adrenal insufficiency (Addison disease), the adrenal cortex cannot respond. In secondary adrenal insufficiency (long-standing pituitary failure), the adrenal cortex has atrophied from lack of ACTH tropic stimulation and also cannot respond acutely, though the defect is upstream.

The insulin tolerance test is the gold standard for assessing the integrity of the entire HPA axis. Insulin-induced hypoglycaemia is a potent physiological stressor that activates the hypothalamus, producing CRH release, ACTH release, and cortisol rise. A normal cortisol response (peak > 18 mcg/dL) confirms integrity of the entire axis from hypothalamus through pituitary to adrenal cortex. Failure to respond localises the defect somewhere in the cascade, necessitating further investigation.

Connections Master

Endocrine hormones and regulation 18.07.01 is the prerequisite unit covering the general principles of hormone classes, receptor mechanisms, and feedback. This unit focuses specifically on the hypothalamic-pituitary axis as the central organising structure of the endocrine system.
Nervous system gross anatomy 18.05.01 and brain regions 18.05.03 pending provide the neuroanatomical context: the hypothalamus sits at the base of the diencephalon, connected to the pituitary via the infundibulum. The supraoptic and paraventricular nuclei are hypothalamic structures with direct neuroendocrine output.
Renal physiology 18.08.01 is regulated by ADH (water reabsorption in the collecting duct), aldosterone (sodium reabsorption, potassium excretion), and atrial natriuretic peptide. SIADH and diabetes insipidus are disorders of the renal-ADH axis.
Cardiovascular physiology 18.02.01 is modulated by cortisol (maintaining vascular responsiveness to catecholamines), ADH (vasoconstriction at high concentrations), and the HPA stress response. Adrenal insufficiency causes hypotension through loss of cortisol-mediated vascular tone.
Reproductive biology 18.09.01 is driven by the HPG axis: GnRH pulsatility, FSH and LH effects on gonadal steroidogenesis, and the feedback regulation by oestradiol, progesterone, and testosterone. Puberty, the menstrual cycle, and menopause are all HPG axis phenomena.
Cell signalling 17.07.01 provides the molecular basis: GnRH, TRH, and CRH receptors are G-protein-coupled receptors; insulin and IGF-1 signal through receptor tyrosine kinases; steroid and thyroid hormones use nuclear receptors. Receptor desensitisation explains why continuous GnRH agonists suppress rather than stimulate.

Historical & philosophical context Master

The concept that the brain controls the pituitary gland, and through it the entire endocrine system, emerged from the work of Geoffrey Harris in the 1940s and 1950s ^{[Harris 1955]}. Harris demonstrated that the portal blood vessels linking the hypothalamus to the anterior pituitary carried chemical signals ("releasing factors") rather than neural signals. His key experiment showed that electrical stimulation of the hypothalamus produced pituitary hormone release even after severing the pituitary stalk, provided the portal vessels regenerated — proving that vascular, not neural, transmission carried the signal. Harris's 1955 monograph Neural Control of the Pituitary Gland established the field of neuroendocrinology.

The specific releasing hormones were isolated in a remarkable decade of competitive biochemistry by Roger Guillemin and Andrew Schally, who independently extracted and characterised TRH (1969), GnRH (1971), and somatostatin (1973) from hundreds of thousands of sheep and pig hypothalami. Each releasing hormone was purified through bioassay-guided fractionation: hypothalamic extracts were fractionated by chromatography, and each fraction was tested for its ability to stimulate or inhibit specific pituitary hormone release. The effort required millions of hypothalami and years of work, and Guillemin and Schally shared the 1977 Nobel Prize with Rosalyn Yalow (for the radioimmunoassay technique that made hormone measurement possible).

The discovery that the pituitary is controlled by hypothalamic hormones, rather than being an autonomous "master gland," resolved a longstanding debate. The older view (promoted by Harvey Cushing, who called the pituitary the "leader of the endocrine orchestra") placed the pituitary at the top of the hierarchy. Harris's work and the subsequent isolation of releasing hormones showed that the hypothalamus sits above the pituitary, and the hypothalamus itself is modulated by higher brain centres and by hormonal feedback. The result is a distributed control architecture with no single master — a pattern that mirrors decentralised control in engineering systems.

The clinical exploitation of GnRH physiology illustrates how understanding feedback dynamics translates directly into therapy. The discovery that pulsatile GnRH stimulates gonadotropin release while continuous GnRH suppresses it (Knobil, 1980) led to both GnRH agonist drugs (leuprolide, goserelin) for conditions requiring hormonal suppression and pulsatile GnRH pumps for treating infertility. The same molecule, delivered at different frequencies, produces opposite clinical effects — a striking demonstration that information in biological systems is carried not just by molecular identity but by temporal pattern.

Bibliography Master

Harris, G. W., Neural Control of the Pituitary Gland (Arnold, 1955).
Schally, A. V., "Aspects of hypothalamic regulation of the pituitary gland", Science 202 (1978), 18-28.
Guillemin, R., "Peptides in the brain: the new endocrinology of the neuron", Science 202 (1978), 390-402.
Burgus, R., Dunn, T. F., Desiderio, D. & Guillemin, R., "Structure moleculaire du facteur hypothalamique hypophysiotrope TRF d'origine ovine: mise en evidence par spectrometrie de masse de la sequence PCA-His-Pro-NH2", Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences 269 (1969), 1870-1873.
Matsuo, H., Baba, Y., Nair, R. M. G., Arimura, A. & Schally, A. V., "Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence", Biochem. Biophys. Res. Commun. 43 (1971), 1334-1339.
Brazeau, P., Vale, W., Burgus, R., Ling, N., Butcher, M., Rivier, J. & Guillemin, R., "Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone", Science 179 (1973), 77-79.
Knobil, E., "The neuroendocrine control of the menstrual cycle", Recent Prog. Horm. Res. 36 (1980), 53-88.
Sherwood, L., Human Physiology: From Cells to Systems, 9th ed. (Cengage, 2016), Ch. 18.
Silverthorn, D. U., Human Physiology: An Integrated Approach, 8th ed. (Pearson, 2019), Ch. 7.
Guyton, A. C. & Hall, J. E., Textbook of Medical Physiology, 14th ed. (Elsevier, 2021), Ch. 74-76.
Melmed, S. et al., Williams Textbook of Endocrinology, 14th ed. (Elsevier, 2019).